Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome

University of Pittsburgh792 enrolled

Overview

The overarching goal of this project is to improve the clinical quality of patients with Benzodiazepine-resistant alcohol withdrawal syndrome.

Study Type

OBSERVATIONAL

Enrollment

792

Conditions

Alcohol Withdrawal Syndrome

Interventions

DiazepamDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: either 1. a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2. \> 40mg of diazepam (or diazepam equivalents) in 1 hr; or 3. an individual dose of 40 mg or greater of intravenous diazepam for control of agitation Exclusion Criteria: * if \< 18 years of age or had evidence of use of other illicit substances as determined by urine toxicology screen

Locations (1)

UPMC

Pittsburgh, Pennsylvania, United States

Outcomes

Primary Outcomes

Identify those risk factors predictive of benzodiazepine-resistant alcohol withdrawal syndrome

Time frame: up to 38 months

Secondary Outcomes

Drug utilization of phenobarbital, propofol, dexmedetomidine, and ketamine in benzodiazepine-resistant alcohol withdrawal syndrome

Will compare the frequency, duration and dosages of the above agents when used for benzodiazepine-resistant alcohol withdrawal

Time frame: Up to 38 months

Effectiveness of phenobarbital, propofol, dexmedetomidine, and ketamine in benzodiazepine-resistant alcohol withdrawal

Comparative markers will include: 1. Presence or absence of the following: delirium tremens, hallucinosis, seizures, or arrhythmias 2. Indication and duration of mechanical intubation 3. Nosocomial infection rates 4. ICU length of stay

Time frame: Up to 38 months

Tolerability of phenobarbital, propofol, dexmedetomidine, and ketamine in benzodiazepine-resistant alcohol withdrawal

Comparative markers will include: 1. Rikers Sedation Scale Assessments 2. Hypotension 3. Hypertriglyceridemia/Pancreatitis 4. Drug induced hallucinosis or seizures

Time frame: Up to 38 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.